$5.41 Billion is the total value of Avoro Capital Advisors LLC's 39 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $691,538,000 | +56.0% | 10,125,000 | +3.3% | 12.78% | +45.8% |
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $317,186,000 | -20.5% | 5,125,000 | +2.5% | 5.86% | -25.6% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $301,404,000 | +10.8% | 3,555,555 | +8.3% | 5.57% | +3.5% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $294,291,000 | +39.2% | 2,850,000 | +25.3% | 5.44% | +30.1% |
| SGEN | Buy | SEAGEN INC | $255,188,000 | -5.4% | 1,865,000 | +22.3% | 4.71% | -11.6% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $114,030,000 | +65.8% | 9,050,000 | +39.2% | 2.11% | +55.0% |
| KRYS | Buy | KRYSTAL BIOTECH INC | $88,868,000 | +25.9% | 1,275,000 | +18.6% | 1.64% | +17.7% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $47,224,000 | +90.4% | 2,169,230 | +72.2% | 0.87% | +78.0% |
| Buy | AADI BIOSCIENCES INC | $40,262,000 | +78.6% | 2,849,402 | +55.8% | 0.74% | +67.2% | |
| GLUE | Buy | MONTE ROSA THERAPEUTICS INC | $27,478,000 | -14.2% | 3,363,333 | +1.6% | 0.51% | -19.7% |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $23,679,000 | +25.4% | 1,450,000 | +11.5% | 0.44% | +17.2% |
| New | AMYLYX PHARMACEUTICALS INC | $18,298,000 | – | 650,000 | +100.0% | 0.34% | – | |
| BCAB | New | BIOATLA INC | $4,428,000 | – | 575,000 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.